



PTO/SB/08a/b (06-03)  
Approved for use through 07/31/2003. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE  
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>Substitute for form 1449A/B/PTO</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/001934
				Filing Date	November 15, 2001
				First Named Inventor	Zoltan Nagy
				Art Unit	1642
				Examiner Name	K. Canella
Sheet	1	of	1	Attorney Docket Number	GPCG-P01-003

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)					
KAC	BA	WO-99/45031		09-10-1999			
KAC	BB	WO-96/17874		06-13-1996			
KAC	BC	WO-00/12560		03-09-2000			
KAC	BD	WO-99/53953		10-28-1999			

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		
KAC	CA	Golding et al., "Common Epitope in Human Immunodeficiency Virus (HIV) I-GP41 and HLA Class II Elicits Immunosuppressive Autoantibodies Capable of Contributing to Immune Dysfunction in HIV I-infected Individuals," The Journal of Clinical Investigation 83:1430-1435 (1989)		
KAC	CB	Golding et al., "Identification of Homologous Regions in Human Immunodeficiency Virus I gp41 and Human MHC Class II $\beta$ 1 Domain," Journal of Experimental Medicine 167:914-923 (1988)		
KAC	CC	Okudaira et al., "Anti-Ia Reactivity in Sera from Patients with Systemic Lupus Erythematosus," J. Clin. Invest. 69:17-24 (1982)		
KAC	CD	Jia Dong Shi et al., "In Vivo Pharmacodynamic Effects of Hu1D10 (Remitogen), a Humanized Antibody Reactive Against a Polymorphic Determinant of HLA-DR Expressed on B Cells," Leukemia and Lymphoma 43:1303-1312 (2002)		
KAC	CE	Newell et al., "Does the Oxidative/Glycolytic Ratio Determine Proliferation or Death in Immune Recognition?" Annals New York Academy of Sciences Pgs. 77-82		
KAC	CF	Bridges et al., "Selective In Vivo Antitumor Effects of Monoclonal Anti-I-A Antibody on B Cell Lymphoma," The Journal of Immunology 139(12):4242-4249 (1987)		

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	/Karen A. Canella, Ph.D./	Date Considered	09/18/2006
-----------------------	---------------------------	--------------------	------------

7/3/2006

PTO/SB/08a/b (07-05)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/001934
				Filing Date	November 15, 2001
				First Named Inventor	Zoltan Nagy
				Art Unit	1643
				Examiner Name	K. A. Canella
Sheet	1	of	1	Attorney Docket Number	GPCG-P01-003

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number Number-Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
KAC	BF	WO 98/37200	08-27-1998	GENENTECH, INC.		

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
KAC	CG	TRUMAN et al., "Lymphocyte programmed cell death is mediated via HLA class II DR", International Immunol. 6(6): 887-96, (1994).	
KAC	CH	BLAKEY et al., "Antibody Toxin Conjugates: A Perspective", Prog. Allergy, Vol. 45, pp 50-90 (1988).	
KAC	CI	SCHLOM, "Monoclonal Antibodies: They're More and Less Than You Think." Molecular Foundation of Oncology pgs 95-134 (1994).	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	/Karen A. Canella, Ph.D./	Date Considered	09/18/2006
-----------------------	---------------------------	--------------------	------------